UK markets open in 1 hour 12 minutes
  • NIKKEI 225

    28,986.80
    -235.97 (-0.81%)
     
  • HANG SENG

    19,801.12
    -121.33 (-0.61%)
     
  • CRUDE OIL

    88.31
    +0.20 (+0.23%)
     
  • GOLD FUTURES

    1,778.00
    +1.30 (+0.07%)
     
  • DOW

    33,980.32
    -171.69 (-0.50%)
     
  • BTC-GBP

    19,473.54
    -644.79 (-3.21%)
     
  • CMC Crypto 200

    558.08
    -14.74 (-2.57%)
     
  • ^IXIC

    12,938.12
    -164.43 (-1.25%)
     
  • ^FTAS

    4,146.49
    -19.89 (-0.48%)
     

Clot Buster Drugs Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2017-2027

·5-min read
ReportLinker
ReportLinker

Segmented By Type (Fibrin Specific Drugs {Tissue Plasminogen Activator, Reteplase, Tenecteplase, Others} v/s Non-Fibrin Specific Drugs {Urokinase, Streptokinase, Plasminogen Activating Complex}), By Application (Myocardial Infarction, Pulmonary Embolism, Deep Vein Thrombosis, Acute Ischemic Strokes, Others), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies), By Region.

New York, July 27, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Clot Buster Drugs Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2017-2027" - https://www.reportlinker.com/p06310352/?utm_source=GNW

The global clot buster drugs market is projected to grow at a significant CAGR during the forecast period, 2023-2027. The market growth can be attributed to the rising incidences of cardiovascular diseases and the surge in demand for effective pharmaceuticals for the immediate response to heart strokes.

Clot buster drugs are heart disease drugs that aid in the dissolution of blood clots caused by vein blockage, a common cause of strokes and heart attacks.Clot buster drugs, also known as thrombolytic therapeutics, are heart medications frequently administered under medical supervision in hospitals via intravenous injection.

The use of these drugs aids in the prevention of ongoing heart damage during a heart attack or deterioration due to an ischemic stroke.

In the next five years, the global clot buster drugs market is expected grow due to an increase in the prevalence of cardiovascular diseases such as heart attacks and strokes.Stroke is the fifth most common cause of death in the United States.

The increasing number of strokes necessitates an immediate response to the situation, where clot buster drugs can help by dissolving the blood clot pooling in the veins, resulting in lower blood pressure.The population’s mortality rate is rising due to strokes, fueling the growth of the global clot buster drug market.

Furthermore, increasing ischemic stroke risks in the global population is expected to support the growth of the global clot buster drugs market over the next five years.

The global clot buster drugs market is segmented based on type, application, distribution channel, regional distribution, and competitive landscape.Based on application, the market is divided into myocardial infarction, pulmonary embolism, deep vein thrombosis, acute ischemic strokes, and others.

The acute ischemic strokes are expected to hold the largest share in the global clot buster drugs market owing to the rising incidences of ischemic strokes among the global population.

Key players operating in the global clot buster devices market are F. Hoffmann-La Roche AG, Taj Pharmaceuticals Limited, Eumedica Pharmaceuticals SA, SEDICO Pharmaceutical Company, Mochida Pharmaceutical Co., Ltd, Medac GmbH, Microbix Biosystems Inc, Crinos S.p.A., among others.

Years considered for this report:

Historical Years: 2017-2020
Base Year: 2021
Estimated Year: 2022
Forecast Period: 2023–2027

Objective of the Study:

• To analyze the historical growth in the market size of the global clot buster drugs from 2017 to 2021.
• To estimate and forecast the market size of global clot buster drugs market from 2023 to 2027 and growth rate until 2027.
• To classify and forecast the global clot buster drugs market based on type, application, distribution channel, region, and company.
• To identify the dominant region or segment in the global clot buster drugs market.
• To identify drivers and challenges for the global clot buster drugs market.
• To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in the global clot buster drugs market.
• To identify and analyze the profiles of leading players operating in the global clot buster drugs market.
• To identify key sustainable strategies adopted by market players in global clot buster drugs market.
The analyst performed both primary as well as exhaustive secondary research for this study.Initially, the analyst sourced a list of manufacturers across the country.

Subsequently, the analyst conducted primary research surveys with the identified companies.While interviewing, the respondents were also enquired about their competitors.

Through this technique, the analyst could include the manufacturers who could not be identified due to the limitations of secondary research. The analyst examined the manufacturers, distribution channels and presence of all major players across the country.
The analyst calculated the market size of the Global clot buster drugs market using a top-down approach, wherein data for various end-user segments was recorded and forecast for the future years. The analyst sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these products and applications for getting an appropriate, overall market size.

Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by the analyst.

Key Target Audience:

• Market research and consulting firms
• Government bodies such as regulating authorities and policy makers
• Organizations, forums, and alliances
The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as product manufacturers, suppliers and partners, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, global clot buster drugs market has been segmented into following categories, in addition to the industry trends which have also been detailed below:
• Clot Buster Drugs Market, By Type:
o Fibrin Specific Drugs
Tissue Plasminogen Activator
Reteplase
Tenecteplase
Others
o Non-Fibrin Specific Drugs
Urokinase
Streptokinase
Plasminogen Activating Complex
• Clot Buster Drugs Market, By Application:
o Myocardial Infarction
o Pulmonary Embolism
o Deep Vein Thrombosis
o Acute Ischemic Strokes
o Others
• Clot Buster Drugs Market, By Distribution Channel:
o Retail Pharmacies
o Hospital Pharmacies
o Online Pharmacies
• Clot Buster Drugs Market, By Region:
o North America
United States
Mexico
Canada
o Europe
France
Germany
United Kingdom
Italy
Spain
o Asia-Pacific
China
India
Japan
South Korea
Australia
o Middle East & Africa
South Africa
Saudi Arabia
UAE
Egypt
o South America
Brazil
Argentina
Colombia

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global clot buster drugs market.

Available Customizations:

With the given market data, we offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).
Read the full report: https://www.reportlinker.com/p06310352/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting